CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 113 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,016,915 | +61.7% | 101,443 | +19.3% | 0.99% | +144.9% |
Q1 2022 | $1,866,000 | -44.5% | 85,000 | -28.2% | 0.40% | -66.4% |
Q4 2021 | $3,362,000 | +6.5% | 118,344 | -21.1% | 1.20% | +30.6% |
Q3 2021 | $3,158,000 | -31.1% | 150,000 | -38.3% | 0.92% | -26.8% |
Q2 2021 | $4,586,000 | – | 243,309 | – | 1.26% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 2,030,616 | $31,028,000 | 6.04% |
5AM Venture Management, LLC | 1,362,286 | $20,816,000 | 3.75% |
Burrage Capital Management LLC | 272,393 | $4,162,000 | 3.37% |
Altium Capital Management LP | 361,930 | $5,530,000 | 1.54% |
Vivo Capital, LLC | 2,214,138 | $33,832,000 | 1.19% |
Bain Capital Life Sciences Investors, LLC | 1,071,428 | $16,371,000 | 0.93% |
Perceptive Advisors | 3,659,381 | $51,606,000 | 0.65% |
New Leaf Venture Partners, L.L.C. | 141,000 | $2,154,000 | 0.50% |
DRIEHAUS CAPITAL MANAGEMENT LLC | 2,003,688 | $30,616,000 | 0.45% |
Opaleye Management Inc. | 188,000 | $2,873,000 | 0.42% |